Clinical trial
GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects…
NCT00280865 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00280865 |
|---|---|
| Title | GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes |
| Official title | Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes |
| Intervention type | Behavioral, Drug |
| Interventions | Tesaglitazar, Pioglitazone, Dietary and Lifestyle Modification Counseling |
| Enrollment | 500 |
| Start date | Apr 1, 2002 |
| Completion | Jun 1, 2003 |
| First posted | Jan 24, 2006 |
| Last update posted | Jul 31, 2006 |
| Countries | Canada, France, Mexico, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: